BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

864 related articles for article (PubMed ID: 31351879)

  • 1. Recent advances in oncolytic virus-based cancer therapy.
    Fu LQ; Wang SB; Cai MH; Wang XJ; Chen JY; Tong XM; Chen XY; Mou XZ
    Virus Res; 2019 Sep; 270():197675. PubMed ID: 31351879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy.
    Chowaniec H; Ślubowska A; Mroczek M; Borowczyk M; Braszka M; Dworacki G; Dobosz P; Wichtowski M
    Front Immunol; 2024; 15():1375433. PubMed ID: 38576614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic Viruses in Cancer Treatment: A Review.
    Lawler SE; Speranza MC; Cho CF; Chiocca EA
    JAMA Oncol; 2017 Jun; 3(6):841-849. PubMed ID: 27441411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in targeting cancer stem cells using oncolytic viruses.
    Zhang YN; Wang SB; Song SS; Hu PY; Zhou YC; Mou YP; Mou XZ
    Biotechnol Lett; 2020 Jun; 42(6):865-874. PubMed ID: 32166558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fighting Cancer with Viruses: Oncolytic Virus Therapy in China.
    Wei D; Xu J; Liu XY; Chen ZN; Bian H
    Hum Gene Ther; 2018 Feb; 29(2):151-159. PubMed ID: 29284308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
    Marchini A; Scott EM; Rommelaere J
    Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies.
    Gujar S; Pol JG; Kim Y; Lee PW; Kroemer G
    Trends Immunol; 2018 Mar; 39(3):209-221. PubMed ID: 29275092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
    Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
    Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic Virotherapy: A Contest between Apples and Oranges.
    Russell SJ; Peng KW
    Mol Ther; 2017 May; 25(5):1107-1116. PubMed ID: 28392162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic Virotherapy in Glioma Tumors.
    Rius-Rocabert S; García-Romero N; García A; Ayuso-Sacido A; Nistal-Villan E
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic Virotherapy by HSV.
    Watanabe D; Goshima F
    Adv Exp Med Biol; 2018; 1045():63-84. PubMed ID: 29896663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses.
    De Silva N; Atkins H; Kirn DH; Bell JC; Breitbach CJ
    Cytokine Growth Factor Rev; 2010; 21(2-3):135-41. PubMed ID: 20338801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance.
    Schirrmacher V
    Expert Opin Biol Ther; 2015; 15(12):1757-71. PubMed ID: 26436571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Oncolytic Herpes Simplex Virus Talimogene Laherparepvec Shows Promising Efficacy in Neuroendocrine Cancer Cell Lines.
    Kloker LD; Berchtold S; Smirnow I; Schaller M; Fehrenbacher B; Krieg A; Sipos B; Lauer UM
    Neuroendocrinology; 2019; 109(4):346-361. PubMed ID: 31280274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Directing systemic oncolytic viral delivery to tumors via carrier cells.
    Nakashima H; Kaur B; Chiocca EA
    Cytokine Growth Factor Rev; 2010; 21(2-3):119-26. PubMed ID: 20226717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viruses as nanomedicine for cancer.
    Badrinath N; Heo J; Yoo SY
    Int J Nanomedicine; 2016; 11():4835-4847. PubMed ID: 27703350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
    Russell L; Peng KW; Russell SJ; Diaz RM
    BioDrugs; 2019 Oct; 33(5):485-501. PubMed ID: 31321623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy with oncolytic viruses: progress and challenges.
    Shalhout SZ; Miller DM; Emerick KS; Kaufman HL
    Nat Rev Clin Oncol; 2023 Mar; 20(3):160-177. PubMed ID: 36631681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic viruses and histone deacetylase inhibitors--a multi-pronged strategy to target tumor cells.
    Nguyen TL; Wilson MG; Hiscott J
    Cytokine Growth Factor Rev; 2010; 21(2-3):153-9. PubMed ID: 20395162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Oncolytic Viruses in the Treatment of Melanoma.
    Bayan CY; Lopez AT; Gartrell RD; Komatsubara KM; Bogardus M; Rao N; Chen C; Hart TD; Enzler T; Rizk EM; Pradhan JS; Marks DK; Geskin LJ; Saenger YM
    Curr Oncol Rep; 2018 Aug; 20(10):80. PubMed ID: 30145781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.